Johanna Friedl-Naderer - 22 Feb 2023 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role: EVP & Chief Operating Officer
Signature: /s/ Howard Horn, Attorney-in-Fact
Issuer symbol: VIR
Transactions as of: 22 Feb 2023
Net transactions value: $0
Form type: 4
Filing time: 24 Feb 2023, 19:27:45 UTC
Previous filing: 08 Mar 2022
Next filing: 07 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIR	Common Stock	Award	$0	+60,000	+67%	$0.000000	150,000	22 Feb 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIR	Stock Option (Right to Buy)	Award	$0	+70,000		$0.000000	70,000	22 Feb 2023	Common Stock	70,000	$27.01	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2	25% of the shares subject to the stock option vest and become exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter.